Amylin Pharmaceuticals Files Preliminary Prospectus Supplement for Public Offering of Common Stock
January 18 2005 - 6:00AM
PR Newswire (US)
Amylin Pharmaceuticals Files Preliminary Prospectus Supplement for
Public Offering of Common Stock SAN DIEGO, Jan. 18
/PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(NASDAQ:AMLN) today announced that it has filed a preliminary
prospectus supplement to its shelf registration statement with the
Securities and Exchange Commission relating to a proposed
underwritten public offering of 6.5 million shares of its common
stock. To the extent that the underwriters sell more than 6.5
million shares, the company also will grant an over- allotment
option to the underwriters for the purchase of up to an additional
975,000 shares of common stock. All of the shares are being sold by
Amylin Pharmaceuticals. Morgan Stanley & Co. Incorporated is
acting as the sole book running and joint lead manager for the
offering announced today. Goldman, Sachs & Co. is acting as
joint lead manager of the offering. Co-managers for the offering
are Banc of America Securities LLC, J.P. Morgan Securities Inc.,
and Wachovia Capital Markets, LLC. These securities may not be sold
nor may offers to buy be accepted prior to the time that the
prospectus supplement is final. This communication shall not
constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of these securities in any state in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state. The common stock is being offered in connection with a
distribution by the issuer and represents new financing. Amylin
Pharmaceuticals is committed to improving the lives of people with
diabetes and other metabolic diseases through the discovery,
development and commercialization of innovative, cost-effective
medicines. Copies of the preliminary prospectus supplement may be
obtained from the Prospectus Departments of Morgan Stanley &
Co. Incorporated (1585 Broadway, New York, New York 10036, phone
212-761-6775, fax 212-761-0211), Goldman, Sachs & Co. (Attn:
Prospectus Department, 85 Broad Street, New York, New York 10004,
phone 212-902-1171, fax 212-902-9316), Banc of America Securities
LLC (9 West 57th Street, New York, NY 10019, phone 888-583-8900),
J.P. Morgan Securities Inc. (1 Chase Manhattan Plaza, Floor 5B, New
York, New York 10081, phone 212-552-5164) and Wachovia Capital
Markets, LLC (7 St. Paul Street, Baltimore, Maryland 21202, phone
443-263-6400, fax 443-263-6894). DATASOURCE: Amylin
Pharmaceuticals, Inc. CONTACT: Mark G. Foletta, Vice President,
Finance and Chief Financial Officer of Amylin Pharmaceuticals,
Inc., +1-858-552-2200 Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024